Has David Maybee, MD received payments from drug or device companies?

Yes. Drug and device makers reported $992,763 in general payments to David Maybee, MD across 831 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean David Maybee, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about David Maybee, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

David Maybee, MD

Pulmonary Disease · New Bern, NCNPI 1245286467

Payments from drug & device makers

$992,763in general payments, 2019–2025

Across 831 payments — averaging $1194.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$554K
Boehringer Ingelheim$199K
Chiesi USA, Inc.$187K
Boehringer Ingelheim International GmbH$22K
Sanofi US Services Inc.$18K
Novartis$2K
plus $10K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca(2 entities)	98	$554,275
Boehringer Ingelheim	78	$199,038
Chiesi USA, Inc.	48	$186,739
Boehringer Ingelheim International GmbH	56	$21,972
Sanofi US Services Inc.	4	$18,147
Novartis	9	$2,020
GSK	106	$1,492
Inspire Medical Systems, Inc.	9	$1,248
Insmed, Inc.	36	$825
Genentech USA, Inc.	52	$748
Grifols USA, LLC	37	$652
Sanofi	28	$610
Actelion Pharmaceuticals US, Inc.	19	$448
Johnson & Johnson(3 entities)	27	$421
Amgen	20	$331
United Therapeutics Corporation	16	$313
Regeneron Healthcare Solutions, Inc.	12	$247
Merck	12	$229
Lundbeck LLC	8	$171
Pfizer	11	$149
Akcea Therapeutics, Inc.	1	$144
ANI Pharmaceuticals, Inc.	6	$132
Mallinckrodt Hospital Products Inc.	6	$126
CSL Behring	7	$115
Novo Nordisk	7	$104
Gilead	8	$102
Teva Pharmaceuticals USA, Inc.	6	$101
Sanofi-aventis U.S. LLC	3	$98
Lilly USA, LLC	6	$96
Banner Life Sciences, LLC	3	$89
Verona Pharma, Inc.	4	$87
Daiichi Sankyo Inc.	5	$84
Takeda Pharmaceuticals U.S.A., Inc.	4	$82
Sunovion Pharmaceuticals Inc.	6	$74
EMD Serono, Inc.	2	$67
Amarin Pharma, Inc.	5	$65
Azurity Pharmaceuticals, Inc.	3	$62
AbbVie(2 entities)	4	$57
Philips North America LLC	4	$56
Viatris Specialty LLC	3	$52
Vifor Pharma, Inc.	3	$51
Biohaven Pharmaceuticals, Inc.	4	$50
Medtronic	3	$49
Mylan Specialty L.p.	1	$47
Argenx US, Inc.	2	$43
Biohaven Pharmaceutical Holding Company Ltd.	3	$43
Baxter Healthcare	2	$37
Harmony Biosciences LLC	2	$35
Arbor Pharmaceuticals, Inc.	2	$32
Kyowa Kirin, Inc.	2	$29
Alnylam Pharmaceuticals Inc.	1	$28
Radius Health, Inc.	1	$27
Jazz Pharmaceuticals Inc.	2	$27
Mallinckrodt Enterprises LLC	2	$26
Amneal Pharmaceuticals LLC	2	$24
Corium, LLC	1	$24
UCB, Inc.	1	$24
Sandoz	1	$23
Esperion Therapeutics, Inc.	1	$21
Neurocrine Biosciences, Inc.	1	$20

How this compares

$992,763 in reported general payments places this provider in the 95th percentile of 393 pulmonary disease providers in North Carolina.

See all pulmonary disease providers in North Carolina →

Medicare billing

Part B allowed, 2024

$507,065

Medicare patients

1,020

Services billed

23,422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in New Bern

Selwyn SpangenthalCharlotte$7M
Thomas SternHuntersville$5.2M
Laurie SnyderDurham$3.8M
Scott PalmerDurham$3.8M
Michael PritchettPinehurst$2.2M
Anup BanerjeeGastonia$2.1M
Hubert FordChapel Hill$2M
Murali RamaswamyGreensboro$2M
Mikell JarrattGastonia$1.7M
Lake MorrisonDurham$1.6M

See the full list for North Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →